Compounds > 4-phospho-d-erythronohydroxamic acid
Page last updated: 2024-12-08

4-phospho-d-erythronohydroxamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID449303
CHEMBL ID116018
SCHEMBL ID2219243
MeSH IDM0508452

Synonyms (17)

Synonym
phosphoric acid mono-((1r,3r)-2,3-dihydroxy-3-hydroxycarbamoyl-propyl) ester
bdbm50148767
2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate
4-phospho-d-erythronohydroxamic acid
RES ,
DB04496 ,
2BES
[(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl] dihydrogen phosphate
CHEMBL116018 ,
718599-64-5
SCHEMBL2219243
DTXSID10332304
(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate
PD059244
(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyldihydrogenphosphate
1310908-09-8
rel-(2r,3r)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl dihydrogen phosphate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" A virtual fragment screen was undertaken of the enzyme to discover starting points for the development of inhibitors which are likely to have appropriate physicochemical properties for an orally bioavailable compound."( Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
Alibu, VP; Barrett, MP; Brenk, R; Campbell, G; Gilbert, IH; Ruda, GF, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
6-phosphogluconate dehydrogenase, decarboxylatingOvis aries (sheep)Ki2.54002.54002.54002.5400AID492275
6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)Ki1.27500.01002.74508.3000AID7236; AID7238
6-phosphogluconate dehydrogenase, decarboxylating Trypanosoma brucei brucei TREU927Ki0.01000.01000.01000.0100AID594837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
pentose-phosphate shunt6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose-phosphate shunt, oxidative branch6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose biosynthetic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
D-gluconate catabolic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
phosphogluconate dehydrogenase (decarboxylating) activity6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
NADP binding6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleus6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
extracellular exosome6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID215359In vitro antiparasitic activity was determined against Trypanosoma brucei2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID7236Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID492275Inhibition of sheep 6PGDH expressed in Escherichia coli by spectroscopy2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID594837Inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
AID7238Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID229393Selectivity ratio of inhibition constant of compound against 6-phosphogluconate dehydrogenase of sheep to 6-phosphogluconate dehydrogenase of Trypanosoma brucei2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID1693212Competitive inhibition of recombinant poly-His-tagged Trypanosoma cruzi Ribose 5-phosphate isomerase type B expressed in Escherichia coli BL21 codon plus (DE3) using ribose 5-phosphate as substrate
AID158531In vitro antiparasitic activity against Plasmodium falciparum2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID594838Inhibition of Mycobacterium tuberculosis rpiB2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
AID213662In vitro antiparasitic activity was determined against Trypanosoma cruzi2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID99666In vitro cytotoxic activity against L6 cells2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID1126501Binding affinity to Pseudomonas aeruginosa KdsD expressed Escherichia coli at 5 mM after 2 to 3 days by STD-NMR analysis2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Arabinose 5-phosphate isomerase as a target for antibacterial design: studies with substrate analogues and inhibitors.
AID492273Inhibition of Trypanosoma brucei 6PGDH expressed in Escherichia coli by spectroscopy2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID100416In vitro antiparasitic activity was determined against Leishmania donovani2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID594836Inhibition of Francisella tularensis N-terminal hexahistidine-tagged arabinose phosphate isomerase expressed in Escherichia coli BL21(DE3) after 3 hrs2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phosphoglycolohydroxamate
phosphoglycolohydroxamate: inhibits DHAP (dihydroxyacetone phosphate)-converting enzymes; structure. phosphoglycolohydroxamic acid : The hydroxamate of phosphoglycolic acid.		2.0610amidoalkyl phosphate;
hydroxamic acid		EC 5.3.1.1 (triose-phosphate isomerase) inhibitor
phenylmethanesulfonic acid
phenylmethanesulfonic acid: RN given refers to parent cpd		2.0510
cysteic acid
Cysteic Acid: Beta-Sulfoalanine. An amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.. cysteic acid : An amino sulfonic acid that is the sulfonic acid analogue of cysteine.		2.0510alanine derivative;
amino sulfonic acid;
carboxyalkanesulfonic acid;
cysteine derivative;
non-proteinogenic alpha-amino acid		animal metabolite
4-phosphoerythronate
4-phosphoerythronate: inhibits ribose-5-phosphate isomerase. 4-phospho-D-erythronic acid : The D-enantiomer of 4-phosphoerythronic acid.		2.73304-phosphoerythronic acidEscherichia coli metabolite;
mouse metabolite
Thieno[3,2-b]thiophene-2-carboxylic acid
[no description available]		2.0510thienothiophene
ConditionIndicatedRelationship StrengthStudiesTrials
African Sleeping Sickness
[description not available]		02.0510
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		02.0510